News

Researchers at the Ontario Institute for Cancer Research have identified a genetic variation on chromosome 8 associated with colorectal cancer.

Roche Diagnostics now owns the patents for Electrochemiluminescence technology and can expand its immunochemistry into new market segments.

UT Southwestern researchers determined how a substance derived from the bark of the South American lapacho tree kills certain kinds of cancer cells.

Weill Cornell researchers have uncovered two new potential points of vulnerability on a key cancer-promoting protein, called XIAP.

Abraxis exclusively licenses property portfolio designed to personalize treatment for colorectal cancer from the University of Southern California.

Duke researchers have opened up a new way to screen drugs for possible heart-related side effects and to develop new drugs.

The extended agreement allows Abbott to retain exclusive rights to 10 targets in lung cancer identified by Caprion for up to two years.

QIAGEN and Digene have announced a definitive agreement to combine the two companies to create market- and technology-leadership in molecular diagnostics.

The long-term goal of the initiative is to shed light on the causes of complex disorders and diseases and develop new approaches for treating them.

The research agreement between Immunicon and Bristol-Myers Squibb involve protein and molecular targets associated with circulating tumor cells.